MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 0.5% Higher - Should You Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report)'s share price rose 0.5% during trading on Tuesday . The company traded as high as $1.89 and last traded at $1.84. Approximately 126,674 shares traded hands during trading, a decline of 45% from the average daily volume of 229,457 shares. The stock had previously closed at $1.83.

MAIA Biotechnology Price Performance

The stock has a fifty day moving average of $1.82 and a 200 day moving average of $1.89. The firm has a market capitalization of $55.16 million, a P/E ratio of -2.30 and a beta of 0.03.

Insider Buying and Selling at MAIA Biotechnology

In related news, Director Stan Smith purchased 33,333 shares of MAIA Biotechnology stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average cost of $1.50 per share, for a total transaction of $49,999.50. Following the completion of the transaction, the director owned 1,305,059 shares in the company, valued at $1,957,588.50. This trade represents a 2.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 32.32% of the company's stock.

Hedge Funds Weigh In On MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Jane Street Group LLC bought a new stake in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned about 0.15% of MAIA Biotechnology at the end of the most recent quarter. Hedge funds and other institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.